Updated for:

Thursday, April 17, 2014 5:26 PM

The Sentinel Newspapers

Helpful Tools

Subscribe to:

  • RSS

FDA approves marijuana based drug

Share This Article:

Published on: Thursday, October 31, 2013

By Bonnie Katz

The U.S. Food and Drug Administration has approved clinical trials of a cannabis-based drug and its effects on epilepsy. The treatment, Epidiolex, is 98 percent purified cannabidiol (CBD) made by GW Pharmaceuticals based out of the U.K.  

There are around 60 known chemicals contained in cannabis called cannabinoids. Tetrahydrocannabinol, also known as THC, is the main component responsible for the drug’s psychoactive nature. CBD, however, is the second most abundant cannabinoid in the cannabis and provides medicinal benefits without the “high.” Epidiolex will come in a viscous liquid form to be dispensed from syringes. A 25 milligram per meter or 100 milligram per meter will be the two strengths made available to those in the trials.

The FDA has approved of intermediate-sized clinical trials sponsored by two doctors. Dr. Orrin Devinsky, a professor in the Department of Neurology, Neuroscience and Psychiatry in the New York University School of Medicine and director of the NYU Comprehensive Epilepsy Center, and Dr. Roberta Cilio, a pediatric neurologist at the University of California, San Francisco, are set to follow 25 patients using Epidiolex as treatment for pediatric epilepsy.

On Oct. 4, at the NYU Langone Medical Center, Devinsky led a conference entitled, “Cannabidiols: Potential Use in Epilepsy & Other Neurological Disorders.” During the affair, Devinsky and Cilio led a presentation on planned trials on CBD in children with treatment resistant epilepsy.

The D.C. - based Marijuana Policy Project’s Communications Director Mason Tvert responded to the news of the approved trials. “We’ve long known that marijuana has a variety of medical benefits,” Tvert said. Tvert added that the federal government clearly recognizes marijuana’s medicinal benefits and it’s a shame they hindered most research of it.

Maryland’s new marijuana law came into effect on Oct. 1, but its miniscule scope won’t have much effect. It deals with a small number of patients that would enroll in state-approved clinical studies. However, with no hospitals signed up to hold these studies, no visible changes are set to occur in the near future.

Now the country will wait and see if CBD can live up to the hype, and if the epileptic patients can find any relief from their disease. 

Reader Comments - 1 Total

captcha b53cdd96f4964931a538013040b54f3c

Posted By: Storm Crow On: 10/31/2013

Title: It is about freaking time!

CBD will MORE than "live up to the hype"! Besides epilepsy, CBD can stop the growth of aggressive cancers. Read "Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells" (PubMed) or "Pot compound seen as tool against cancer" (SFGate). When it comes to diabetes, CBD is you new best friend! “Lab Notes: Pot Has Benefits for Diabetic Hearts” (MedPageToday), “Marijuana Compound May Help Stop Diabetic Retinopathy” (ScienceDaily) and "Beneficial effects of a Cannabis sativa extract on diabetes induced neuropathy and oxidative stress" (PubMed). And if you are trying to quit tobacco, you HAVE to read "Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings"! And that is just the start of what cannabidiol can do for you! More can be found in "Granny Storm Crow's List" - free online and on facebook.


Today's Poll

Question: What's your tablet of choice?
  • iPad
  • Kindle
  • Samsung Galaxy
  • Any tablet is fine
  • I don't use tablets

Current Issue

This Week's Issue

Thursday, April 17, 2014